Loading…

Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast

Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overc...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2024-10, Vol.17 (11), p.1415
Main Authors: Jeong, Ji-Su, Ha, Eun-Sol, Park, Heejun, Lee, Seon-Kwang, Kang, Hui-Taek, Kim, Min-Soo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243
container_end_page
container_issue 11
container_start_page 1415
container_title Pharmaceuticals (Basel, Switzerland)
container_volume 17
creator Jeong, Ji-Su
Ha, Eun-Sol
Park, Heejun
Lee, Seon-Kwang
Kang, Hui-Taek
Kim, Min-Soo
description Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast. Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated. The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations. Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.
doi_str_mv 10.3390/ph17111415
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9f68a78089a0440a989f6263c71be275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A818467891</galeid><doaj_id>oai_doaj_org_article_9f68a78089a0440a989f6263c71be275</doaj_id><sourcerecordid>A818467891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</originalsourceid><addsrcrecordid>eNptks-LEzEUgAdR3LV68Q-QAS8idM2vmSQnKaXqQsGD68VLyGRepikzSU1Sof-96XZdW5EcXnj53hfe41XVa4xuKJXow26DOcaY4eZJdY0ZYXNBGH96dr-qXqS0RajhhXpeXVHZSEEJv65-rKwFk-tg66XL0Zl6YVxfa9_XdzFMkDd6ch7q4Ou8gfpb1p0bXT4cC1YH6GPYpXoZfNbOOz_Ua2ddhiHqlF9Wz6weE7x6iLPq-6fV3fLLfP318-1ysZ4bRmSecyBGWgYIEWIEZ4howG3LmcHCtBJ6jq1tWgKM9L02AB3XmMu25x1FQBidVbcnbx_0Vu2im3Q8qKCduk-EOCgdszMjKGlboblAQmrEGNJSlAxpqeG4A8Kb4vp4cu323QS9AZ-jHi-kly_ebdQQfimMG8kF4cXw7sEQw889pKwmlwyMo_YQ9klRTClrES5xVr39B92GffRlVvcUJlLwM2rQpQPnbSgfm6NULQQWrOVCHqmb_1Dl9DA5EzxYV_IXBe9PBSaGlCLYxyYxUse1Un_XqsBvzsfyiP7ZI_obldzFRA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3133129871</pqid></control><display><type>article</type><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</creator><creatorcontrib>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</creatorcontrib><description>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast. Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated. The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations. Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph17111415</identifier><identifier>PMID: 39598327</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; Antioxidants ; Care and treatment ; Citric acid ; Complications and side effects ; Design of experiments ; Diagnosis ; Dosage and administration ; Drug therapy ; dry eye disease ; Dry eye syndromes ; Eye diseases ; eyedrop formulation ; FDA approval ; Inflammation ; lifitegrast ; Oxidation ; Oxidative stress ; physicochemical stability</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2024-10, Vol.17 (11), p.1415</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3133129871/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3133129871?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39598327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeong, Ji-Su</creatorcontrib><creatorcontrib>Ha, Eun-Sol</creatorcontrib><creatorcontrib>Park, Heejun</creatorcontrib><creatorcontrib>Lee, Seon-Kwang</creatorcontrib><creatorcontrib>Kang, Hui-Taek</creatorcontrib><creatorcontrib>Kim, Min-Soo</creatorcontrib><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast. Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated. The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations. Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</description><subject>Acids</subject><subject>Antioxidants</subject><subject>Care and treatment</subject><subject>Citric acid</subject><subject>Complications and side effects</subject><subject>Design of experiments</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>dry eye disease</subject><subject>Dry eye syndromes</subject><subject>Eye diseases</subject><subject>eyedrop formulation</subject><subject>FDA approval</subject><subject>Inflammation</subject><subject>lifitegrast</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>physicochemical stability</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks-LEzEUgAdR3LV68Q-QAS8idM2vmSQnKaXqQsGD68VLyGRepikzSU1Sof-96XZdW5EcXnj53hfe41XVa4xuKJXow26DOcaY4eZJdY0ZYXNBGH96dr-qXqS0RajhhXpeXVHZSEEJv65-rKwFk-tg66XL0Zl6YVxfa9_XdzFMkDd6ch7q4Ou8gfpb1p0bXT4cC1YH6GPYpXoZfNbOOz_Ua2ddhiHqlF9Wz6weE7x6iLPq-6fV3fLLfP318-1ysZ4bRmSecyBGWgYIEWIEZ4howG3LmcHCtBJ6jq1tWgKM9L02AB3XmMu25x1FQBidVbcnbx_0Vu2im3Q8qKCduk-EOCgdszMjKGlboblAQmrEGNJSlAxpqeG4A8Kb4vp4cu323QS9AZ-jHi-kly_ebdQQfimMG8kF4cXw7sEQw889pKwmlwyMo_YQ9klRTClrES5xVr39B92GffRlVvcUJlLwM2rQpQPnbSgfm6NULQQWrOVCHqmb_1Dl9DA5EzxYV_IXBe9PBSaGlCLYxyYxUse1Un_XqsBvzsfyiP7ZI_obldzFRA</recordid><startdate>20241023</startdate><enddate>20241023</enddate><creator>Jeong, Ji-Su</creator><creator>Ha, Eun-Sol</creator><creator>Park, Heejun</creator><creator>Lee, Seon-Kwang</creator><creator>Kang, Hui-Taek</creator><creator>Kim, Min-Soo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241023</creationdate><title>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</title><author>Jeong, Ji-Su ; Ha, Eun-Sol ; Park, Heejun ; Lee, Seon-Kwang ; Kang, Hui-Taek ; Kim, Min-Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antioxidants</topic><topic>Care and treatment</topic><topic>Citric acid</topic><topic>Complications and side effects</topic><topic>Design of experiments</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>dry eye disease</topic><topic>Dry eye syndromes</topic><topic>Eye diseases</topic><topic>eyedrop formulation</topic><topic>FDA approval</topic><topic>Inflammation</topic><topic>lifitegrast</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>physicochemical stability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeong, Ji-Su</creatorcontrib><creatorcontrib>Ha, Eun-Sol</creatorcontrib><creatorcontrib>Park, Heejun</creatorcontrib><creatorcontrib>Lee, Seon-Kwang</creatorcontrib><creatorcontrib>Kang, Hui-Taek</creatorcontrib><creatorcontrib>Kim, Min-Soo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeong, Ji-Su</au><au>Ha, Eun-Sol</au><au>Park, Heejun</au><au>Lee, Seon-Kwang</au><au>Kang, Hui-Taek</au><au>Kim, Min-Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2024-10-23</date><risdate>2024</risdate><volume>17</volume><issue>11</issue><spage>1415</spage><pages>1415-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast. Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated. The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations. Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39598327</pmid><doi>10.3390/ph17111415</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals (Basel, Switzerland), 2024-10, Vol.17 (11), p.1415
issn 1424-8247
1424-8247
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9f68a78089a0440a989f6263c71be275
source Publicly Available Content Database; PubMed Central
subjects Acids
Antioxidants
Care and treatment
Citric acid
Complications and side effects
Design of experiments
Diagnosis
Dosage and administration
Drug therapy
dry eye disease
Dry eye syndromes
Eye diseases
eyedrop formulation
FDA approval
Inflammation
lifitegrast
Oxidation
Oxidative stress
physicochemical stability
title Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Citric%20Acid%20and%20Tromethamine%20on%20the%20Stability%20of%20Eyedrops%20Containing%20Lifitegrast&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=Jeong,%20Ji-Su&rft.date=2024-10-23&rft.volume=17&rft.issue=11&rft.spage=1415&rft.pages=1415-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph17111415&rft_dat=%3Cgale_doaj_%3EA818467891%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-7e2c9f4e0022c87402ae16674c18c69ed71ff562e42ddaceeb7a1796d7b30e243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3133129871&rft_id=info:pmid/39598327&rft_galeid=A818467891&rfr_iscdi=true